Epidermal growth factor showed no clear difference in survival rates at 3 years compared with best supportive care (low certainty).
Epidermal growth factor may leads to higher survival rates at 5 years compared with best supportive care (low certainty).
It is very uncertain whether epidermal growth factor changes health‐related quality of life compared with best supportive care (very low certainty).
Epidermal growth factor showed no clear difference in overall survival compared with best supportive care (low certainty).
The review found no eligible studies for this question.
Epidermal growth factor showed no clear difference in participants with at least one serious adverse event compared with best supportive care (low certainty).
Epidermal growth factor led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
Epidermal growth factor (EGF), oral spray showed no clear difference in interruptions to cancer treatment (radiotherapy breaks longer than… compared with placebo; GRADE not reported.
Epidermal growth factor (EGF), oral spray showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.